Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CERO

CERo Therapeutics Holdings Inc

Dec 12 • 12:40PM ET

0.0698

Dollar change -0.0062
Percentage change -8.16	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX INO VXRT PGEN CTMX ADVM TFFP APVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	48.94%	Shs Outstand	147.54M	Perf Week	-63.55%
Market Cap	10.49M	Forward P/E	-	EPS next Y	-	Insider Trans	-9.18%	Shs Float	76.76M	Perf Month	-73.92%
Income	-9.26M	PEG	-	EPS next Q	-	Inst Own	1.45%	Short Float	7.59%	Perf Quarter	-25.11%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-10.36%	Short Ratio	0.09	Perf Half Y	-80.59%
Book/sh	-0.04	P/B	-	EPS next Y	-	ROA	-108.70%	Short Interest	5.83M	Perf Year	-99.36%
Cash/sh	0.02	P/C	3.10	EPS next 5Y	-	ROE	-4090.08%	52W Range	0.06 - 12.80	Perf YTD	-99.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-99.45%	Beta	0.29
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.75%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	-17.53%	Oper. Margin	-	RSI (14)	36.72	Volatility	28.59% 28.16%
Employees	9	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-61.17%	Payout	-	Rel Volume	0.29	Prev Close	0.08
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	66.64M	Price	0.07
SMA20	-60.96%	SMA50	-46.91%	SMA200	-90.16%	Trades		Volume	9,931,112	Change	-8.16%

Dec-06-24 09:00AM	CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO (GlobeNewswire) -39.95%
Nov-15-24 08:45AM	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia (GlobeNewswire) +52.40%
Nov-11-24 08:15AM	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity (GlobeNewswire) +180.00%
Oct-21-24 09:00AM	CERo Therapeutics, Inc. Provides Corporate Update (GlobeNewswire)
Oct-02-24 09:15AM	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer (GlobeNewswire) -14.23%
09:17AM	Loading…
Sep-25-24 09:17AM	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 (GlobeNewswire) +6.72%
Jul-08-24 08:00AM	CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 (GlobeNewswire) -18.46%
Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire) -16.24%
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
YK Bioventures Opportunities G	10% Owner	Dec 06 '24	Sale	0.12	1,236,874	148,425	21,383,909	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 10 '24	Sale	0.09	1,570,947	141,385	18,962,419	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 09 '24	Sale	0.11	850,543	93,560	20,533,366	Dec 10 08:44 PM
SLOAN STUART M	10% Owner	Sep 25 '24	Sale	0.10	532,486	55,538	21,067,956	Nov 20 04:04 PM
YK Bioventures Opportunities G	10% Owner	Oct 10 '24	Sale	0.10	3,250,000	325,000	22,620,783	Nov 14 08:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc

Upgrade your FINVIZ experience